Dasatinib

ArtNr	HY-10181-50mg
Hersteller	MedChem Express
CAS-Nr.	302962-49-8
Menge	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Typ	Inhibitors
Specific against	other
Purity	99.85
Citations	[1]Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61. ACS Omega. October 26, 2022.\|ACS Pharmacol Transl Sci. 2023 May 2.\|Acta Pharmacol Sin. 2024 Jul 23.\|Adv Funct Mater. 27 January 2022.\|Aging. 2020 Jun 25;12(12):11337-11348.\|Artif Cells Nanomed Biotechnol. 2023 Oct 5.\|Behav Brain Res. 2022 Dec 16;114260.\|Biochem Pharmacol. 2023 Jan 30.\|Bioconjug Chem. 2023 Jul 17.\|Biogerontology. 2022 Apr 25:1-15.\|Biol Pharm Bull. 2017;40(10):1747-1753. \|Biomaterials. 16 September 2022.\|Biomed Chromatogr. 2019 Dec;33(12):e4674.\|Biomed Pharmacother. 2023 Apr 12;162:114680.\|Biomed Pharmacother. 2024 Jan 9:171:116124.\|Biomolecules. 2022 Jun 11;12(6):819.\|bioRxiv. 2023 Dec 14.\|bioRxiv. 2024 Jul 30:2024.07.29.605645.\|bioRxiv. 2024 July 19.\|bioRxiv. 2024 Oct 23:2024.10.20.619300.\|bioRxiv. 2025 February 18.\|bioRxiv. 2025 February 26.\|Br J Cancer. 2022 Nov 1.\|Br J Pharmacol. 2024 Aug 8.\|Breast Cancer Res Treat. 2020 Jan;179(2):337-347.\|Cancer Cell Int. 2021 Jun 5;21(1):291.\|Cancer Cell Int. 2023 Dec 16;23(1):323.\|Cancer Cell. 2025 Mar 13:S1535-6108(25)00070-4.\|Cancers (Basel). 2022 Mar 11;14(6):1451.\|Cell Biochem Funct. 2020 Jul;38(5):642-650.\|Cell Commun Signal. 2024 Feb 12;22(1):115.\|Cell Death Dis. 2021 Dec 3;12(12):1126.\|Cell Death Dis. 2025 Feb 3;16(1):64.\|Cell Mol Gastroenterol Hepatol. 2022 Apr 2;14(1):75-99.\|Cell Signal. 2024 Oct.\|Cell. 2021 Oct 28;184(22):5670-5685.e23.\|Cells. 2023 Dec 14, 12(24), 2836.\|Chem Biol Interact. 2021 Oct 27;109729.\|Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775.\|Clin Sci. 2021 Jul 20;CS20210571.\|Discov Oncol. 2024 Nov 19;15(1):678.\|Diseases. 2023 Oct 23;11(4):147.\|Drug Des Devel Ther. 2024 Dec 5:18:5641-5654.\|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.\|Eur J Pharmacol. 2021 Feb 10;173944.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Exp Eye Res. 2022 Aug 2;223:109207.\|FASEB J. 2024 Jan;38(1):e23355.\|FEBS J. 2024 Oct 20.\|Front Cell Dev Biol. 2021 Mar 16;9:618045.\|Front Microbiol. 2019 Aug 7;10:1816.\|Front Pharmacol. 2021 Mar 8;12:644342.\|Harvard Medical School LINCS LIBRARY\|Hear Res. 2024 Dec 4:455:109165.\|Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231188492.\|Immunity. 2024 Mar 12;57(3):513-527.e6.\|Int J Biol Sci. 2025 Jan 6;21(3):940-954.\|Int J Med Sci. 2025 Jan 1;22(1):110-120.\|Int J Rheum Dis. 2023 Feb 21.\|iScience. 2023 Jul 21.\|J Anim Sci Biotechnol. 2021 May 10;12(1):63.\|J Cancer Res Clin Oncol. 2022 Nov 19.\|J Chem Inf Model. 2024 Jun 7.\|J Clin Invest. 2019 Mar 1;129(3):972-987.\|J Clin Invest. 2023 Feb 16;e162324.\|J Hematol Oncol. 2022 Apr 29;15(1):46.\|J Hematol Oncol. 2024 Dec 18;17(1):122.\|J Immunol Res. 2022 Apr 28;2022:6324326.\|J Immunother Cancer. 2020 Mar;8(1):e000111. \|J Med Chem. 2021 Mar 11;64(5):2725-2738.\|J Med Chem. 2021 Sep 21.\|J Med Chem. 2024 Nov 28;67(22):20571-20579.\|J Pharm Anal. 2021 Jun 19.\|J Pineal Res. 2019 Sep;67(2):e12588. \|J Prosthodont Res. 2025 Feb 11.\|J Toxicol Sci. 2024;49(8):337-348.\|J Transl Med. 2022 Jun 21;20(1):278.\|J Virol. 2024 Sep 17:e0112924.\|JCI Insight. 2025 Jan 23;10(2):e180248.\|Kawasaki Medical Journal. 43(2)：63-78，2017.\|Leukemia. 2012 Oct;26(10):2233-44.\|Leukemia. 2020 Jun;34(6):1524-1539. \|Matrix Biol. 2024 Mar:127:48-56.\|Med Oncol. 2022 Dec 16;40(1):49.\|Mol Ther. 2023 Feb 28;S1525-0016(23)00116-8.\|Molecules. 2018 Mar 23;23(4). pii: E736.\|Nat Aging. 2024 Apr;4(4):527-545.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Cell Biol. 2023 Mar;25(3):493-507.\|Nat Commun. 2020 Apr 14;11(1):1790.\|Nat Commun. 2020 Apr 20;11(1):1913. \|Oncogenesis. 2022 Apr 11;11(1):15.\|Oncotarget. 2016 Aug 30;7(35):56241-56252. \|Patent. US10174018B2.\|Patent. US20180099959A1.\|Patent. US20180099960A1.\|Patent. US20180099961A1.\|Patent. US20180263995A1.\|Patent. US20230226111A1.\|Patent. US20240238271A1.\|Patent. US20240319170A1\|Patent. US20240325538A1.\|PLoS One. 2013;8(2):e56473.\|PLoS One. 2018 Jun 14;13(6):e0199208.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Purdue University. Department of Chemistry.\|Sci Adv. 2024 Dec 13;10(50):eadq4274.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|SSRN. 2024 Apr 1.\|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.\|Target Oncol. 2020 Oct;15(5):659-671.\|Technical University of Munich. 24.01.2018.\|University of Düsseldorf. 2024.\|Front Pharmacol. 2023 Aug 29;14:1250383.\|J Hematol Oncol. 2018 Aug 29;11(1):109. \|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. \|Int J Pharm Res Allied Sci. 2023 Mar;13(1):139-148.
Smiles	O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BMS-354825
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; Bcr-Abl; Src
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	488.017
Product Description	Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of [1]. Dasatinib also induces apoptosis and autophagy.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 125 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK
Isoform	Bcr-Abl
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-10181-50mg-safety-datasheet.pdf